MTEX Mannatech Inc.

Mannatech Introduces Men’s PRIME 7™ to Support Men’s Endocrine Health, Mood, Energy and Libido

Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company, has introduced a , which is specifically designed for men over 30 who want to feel healthy, energetic and strong. Men’s PRIME 7 is a comprehensive health product formulated to support men’s endocrine health, mood, energy and libido.*

This press release features multimedia. View the full release here:

“The good days aren’t over - get your prime back!” said Mannatech President & CEO, Al Bala. “Our new Men’s PRIME 7 is designed to help men over 30 feel like they did when they were in their prime!”

According to Tait Switzer, VP of Research and Development at Mannatech, new Mannatech Men’s PRIME 7 capsules may:

  1. Improve sex drive & libido*
  2. Support healthy erectile function*
  3. Improve stamina & vitality*
  4. Support healthy testosterone levels*
  5. Support prostate health & healthy urinary tract*
  6. Support cardiovascular health*
  7. Support mood and help maintain normal hormonal balance*

“We’ve combined the best science with all-natural ingredients and infused it with Mannatech glyconutrients. It does more than just support healthy testosterone levels or provide prostate support,” said Bala. “Men’s PRIME 7 supports men’s endocrine health, mood, energy and libido. It helps men to feel healthy, energetic and strong!*”

New Mannatech Men’s PRIME 7 is available only for a limited time, through December 31, 2018 or while supplies last.

About Mannatech

Mannatech, Incorporated, offers a profound wellness experience that makes a difference in the lives of people across the world. Through its innovative Glyconutrition products, Mannatech changes lives, providing an unprecedented level of natural wellness, freedom and purpose. With more than 20 years of experience and operations in 25 markets^, Mannatech is committed to changing lives. For more information, visit .

 about Mannatech’s forward-looking statements.

^Mannatech operates in China under a cross-border e-commerce platform that is separate from its multi-level marketing model.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

Glyconutrients are beneficial saccharides found in nature

©2018 Mannatech, Incorporated. All rights reserved. Mannatech and Men’s PRIME 7 are trademarks for Mannatech, Incorporated.

EN
02/10/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mannatech Inc.

 PRESS RELEASE

Mannatech Reports Financial Results for Third Quarter 2025

Mannatech Reports Financial Results for Third Quarter 2025 FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net s...

 PRESS RELEASE

Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of ...

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the “Board”) appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominat...

 PRESS RELEASE

Mannatech Reports Financial Results for Third Quarter 2024

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease...

 PRESS RELEASE

Mannatech Reports Financial Results for Second Quarter 2024

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease ...

 PRESS RELEASE

Mannatech Announces Appointment of James Clavijo as Chief Financial Of...

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ: LVGN), Guided Therapeutics (OTC: GTHP), Aeterna Zentaris (NASDAQ: AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical c...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch